Top

Published in:

Open Access 01-12-2018 | Review

PSMA-PET based radiotherapy: a review of initial experiences, survey on current practice and future perspectives

Authors: Sebastian Zschaeck, Fabian Lohaus, Marcus Beck, Gregor Habl, Stephanie Kroeze, Constantinos Zamboglou, Stefan Alexander Koerber, Jürgen Debus, Tobias Hölscher, Peter Wust, Ute Ganswindt, Alexander D. J. Baur, Klaus Zöphel, Nikola Cihoric, Matthias Guckenberger, Stephanie E. Combs, Anca Ligia Grosu, Pirus Ghadjar, Claus Belka

Published in: Radiation Oncology | Issue 1/2018

Abstract

⁶⁸Gallium prostate specific membrane antigen (PSMA) ligand positron emission tomography (PET) is an increasingly used imaging modality in prostate cancer, especially in cases of tumor recurrence after curative intended therapy. Owed to the novelty of the PSMA-targeting tracers, clinical evidence on the value of PSMA-PET is moderate but rapidly increasing. State of the art imaging is pivotal for radiotherapy treatment planning as it may affect dose prescription, target delineation and use of concomitant therapy.

This review summarizes the evidence on PSMA-PET imaging from a radiation oncologist’s point of view. Additionally a short survey containing twelve examples of patients and 6 additional questions was performed in seven mayor academic centers with experience in PSMA ligand imaging and the findings are reported here.

Available only for authorised users

Perera M, Papa N, Christidis D, Wetherell D, Hofman MS, Murphy DG, et al. Sensitivity, specificity, and predictors of positive (68)Ga-prostate-specific membrane antigen positron emission tomography in advanced prostate Cancer: a systematic review and meta-analysis. Eur Urol. 2016;70:926–37. https://doi.org/10.1016/j.eururo.2016.06.021.CrossRefPubMed

von Eyben FE, Picchio M, von Eyben R, Rhee H, Bauman G. (68)Ga-labeled prostate-specific membrane antigen ligand positron emission tomography/computed tomography for prostate Cancer: a systematic review and meta-analysis. Eur Urol Focus. 2016; https://doi.org/10.1016/j.euf.2016.11.002.

Eder M, Schäfer M, Bauder-Wüst U, Hull W-E, Wängler C, Mier W, et al. 68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging. Bioconjug Chem. 2012;23:688–97. https://doi.org/10.1021/bc200279b.CrossRefPubMed

Afshar-Oromieh A, Haberkorn U, Eder M, Eisenhut M, Zechmann CM. [68Ga]gallium-labelled PSMA ligand as superior PET tracer for the diagnosis of prostate cancer: comparison with 18F-FECH. Eur J Nucl Med Mol Imaging. 2012;39:1085–6. https://doi.org/10.1007/s00259-012-2069-0.CrossRefPubMed

Afshar-Oromieh A, Malcher A, Eder M, Eisenhut M, Linhart HG, Hadaschik BA, et al. PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur J Nucl Med Mol Imaging. 2013;40:486–95. https://doi.org/10.1007/s00259-012-2298-2.CrossRefPubMed

Sterzing F, Kratochwil C, Fiedler H, Katayama S, Habl G, Kopka K, et al. (68)Ga-PSMA-11 PET/CT: a new technique with high potential for the radiotherapeutic management of prostate cancer patients. Eur J Nucl Med Mol Imaging. 2016;43:34–41. https://doi.org/10.1007/s00259-015-3188-1.CrossRefPubMed

Calais J, Fendler WP, Eiber M, Gartmann J, Chu F-I, Nickols NG, et al. Impact of 68Ga-PSMA-11 PET/CT on the Management of Prostate Cancer Patients with biochemical recurrence. J Nucl Med. 2018;59:434–41. https://doi.org/10.2967/jnumed.117.202945.CrossRefPubMed

Calais J, Czernin J, Cao M, Kishan AU, Hegde JV, Shaverdian N, et al. 68Ga-PSMA-11 PET/CT mapping of prostate Cancer biochemical recurrence after radical prostatectomy in 270 patients with a PSA level of less than 1.0 ng/mL: impact on salvage radiotherapy planning. J Nucl Med. 2018;59:230–7. https://doi.org/10.2967/jnumed.117.201749.CrossRefPubMed

Sheikhbahaei S, Afshar-Oromieh A, Eiber M, Solnes LB, Javadi MS, Ross AE, et al. Pearls and pitfalls in clinical interpretation of prostate-specific membrane antigen (PSMA)-targeted PET imaging. Eur J Nucl Med Mol Imaging. 2017; https://doi.org/10.1007/s00259-017-3780-7.

10.

Dietlein F, Kobe C, Neubauer S, Schmidt M, Stockter S, Fischer T, et al. PSA-stratified performance of (18)F- and (68)Ga-PSMA PET in patients with biochemical recurrence of prostate Cancer. J Nucl Med. 2017;58:947–52. https://doi.org/10.2967/jnumed.116.185538.CrossRefPubMed

11.

Domachevsky L, Bernstine H, Goldberg N, Nidam M, Stern D, Sosna J, et al. Early (68)GA-PSMA PET/MRI acquisition: assessment of lesion detectability and PET metrics in patients with prostate cancer undergoing same-day late PET/CT. Clin Radiol. 2017; https://doi.org/10.1016/j.crad.2017.06.116.

12.

Uprimny C, Kroiss AS, Fritz J, Decristoforo C, Kendler D, von Guggenberg E, et al. Early PET imaging with [68]Ga-PSMA-11 increases the detection rate of local recurrence in prostate cancer patients with biochemical recurrence. Eur J Nucl Med Mol Imaging. 2017;44:1647–55. https://doi.org/10.1007/s00259-017-3743-z.CrossRefPubMed

13.

Roach PJ, Francis R, Emmett L, Hsiao E, Kneebone A, Hruby G, et al. The impact of (68)Ga-PSMA PET/CT on management intent in prostate cancer: results of an Australian prospective multicenter study. J Nucl Med. 2017; https://doi.org/10.2967/jnumed.117.197160.

14.

Dewes S, Schiller K, Sauter K, Eiber M, Maurer T, Schwaiger M, et al. Integration of (68)Ga-PSMA-PET imaging in planning of primary definitive radiotherapy in prostate cancer: a retrospective study. Radiat Oncol. 2016;11:73. https://doi.org/10.1186/s13014-016-0646-2.CrossRefPubMedPubMedCentral

15.

Budäus L, Leyh-Bannurah S-R, Salomon G, Michl U, Heinzer H, Huland H, et al. Initial experience of (68)Ga-PSMA PET/CT imaging in high-risk prostate Cancer patients prior to radical prostatectomy. Eur Urol. 2016;69:393–6. https://doi.org/10.1016/j.eururo.2015.06.010.CrossRefPubMed

16.

Herlemann A, Wenter V, Kretschmer A, Thierfelder KM, Bartenstein P, Faber C, et al. 68Ga-PSMA positron emission tomography/computed tomography provides accurate staging of lymph node regions prior to lymph node dissection in patients with prostate Cancer. Eur Urol. 2016;70:553–7. https://doi.org/10.1016/j.eururo.2015.12.051.CrossRefPubMed

17.

van Leeuwen PJ, Emmett L, Ho B, Delprado W, Ting F, Nguyen Q, et al. Prospective evaluation of 68Gallium-prostate-specific membrane antigen positron emission tomography/computed tomography for preoperative lymph node staging in prostate cancer. BJU Int. 2017;119:209–15. https://doi.org/10.1111/bju.13540.CrossRefPubMed

18.

Fendler WP, Schmidt DF, Wenter V, Thierfelder KM, Zach C, Stief C, et al. 68Ga-PSMA PET/CT detects the location and extent of primary prostate Cancer. J Nucl Med. 2016;57:1720–5. https://doi.org/10.2967/jnumed.116.172627.CrossRefPubMed

19.

Maurer T, Gschwend JE, Rauscher I, Souvatzoglou M, Haller B, Weirich G, et al. Diagnostic efficacy of (68)gallium-PSMA positron emission tomography compared to conventional imaging for lymph node staging of 130 consecutive patients with intermediate to high risk prostate Cancer. J Urol. 2016;195:1436–43. https://doi.org/10.1016/j.juro.2015.12.025.CrossRefPubMed

20.

Rhee H, Thomas P, Shepherd B, Gustafson S, Vela I, Russell PJ, et al. Prostate specific membrane antigen positron emission tomography may improve the diagnostic accuracy of multiparametric magnetic resonance imaging in localized prostate Cancer. J Urol. 2016;196:1261–7. https://doi.org/10.1016/j.juro.2016.02.3000.CrossRefPubMed

21.

Zamboglou C, Wieser G, Hennies S, Rempel I, Kirste S, Soschynski M, et al. MRI versus ⁶⁸Ga-PSMA PET/CT for gross tumour volume delineation in radiation treatment planning of primary prostate cancer. Eur J Nucl Med Mol Imaging. 2016;43:889–97. https://doi.org/10.1007/s00259-015-3257-5.CrossRefPubMed

22.

Eiber M, Weirich G, Holzapfel K, Souvatzoglou M, Haller B, Rauscher I, et al. Simultaneous (68)Ga-PSMA HBED-CC PET/MRI improves the localization of primary prostate Cancer. Eur Urol. 2016;70:829–36. https://doi.org/10.1016/j.eururo.2015.12.053.CrossRefPubMed

23.

Zamboglou C, Schiller F, Fechter T, Wieser G, Jilg CA, Chirindel A, et al. (68)Ga-HBED-CC-PSMA PET/CT versus histopathology in primary localized prostate Cancer: a voxel-wise comparison. Theranostics. 2016;6:1619–28. https://doi.org/10.7150/thno.15344.CrossRefPubMedPubMedCentral

24.

Koukourakis MI, Giatromanolaki A, Panteliadou M, Pouliliou SE, Chondrou PS, Mavropoulou S, et al. Lactate dehydrogenase 5 isoenzyme overexpression defines resistance of prostate cancer to radiotherapy. Br J Cancer. 2014;110:2217–23. https://doi.org/10.1038/bjc.2014.158.CrossRefPubMedPubMedCentral

25.

Chang L, Graham PH, Hao J, Bucci J, Cozzi PJ, Kearsley JH, et al. Emerging roles of radioresistance in prostate cancer metastasis and radiation therapy. Cancer Metastasis Rev. 2014;33:469–96. https://doi.org/10.1007/s10555-014-9493-5.CrossRefPubMed

26.

Rao BR, Slotman BJ, Geldof AA, Perez CA. Radiation sensitivity of Copenhagen rat prostatic carcinoma (R3327-AT and R3327-MATLyLu). Int J Radiat Oncol Biol Phys. 1991;20:981–5.CrossRefPubMed

27.

De-Colle C, Yaromina A, Hennenlotter J, Thames H, Mueller A-C, Neumann T, et al. Ex vivo γH2AX radiation sensitivity assay in prostate cancer: inter-patient and intra-patient heterogeneity. Radiother Oncol. 2017;124:386–94. https://doi.org/10.1016/j.radonc.2017.08.020.CrossRefPubMed

28.

Bentzen SM. Theragnostic imaging for radiation oncology: dose-painting by numbers. Lancet Oncol. 2005;6:112–7. https://doi.org/10.1016/S1470-2045(05)01737-7.CrossRefPubMed

29.

Zamboglou C, Drendel V, Jilg CA, Rischke HC, Beck TI, Schultze-Seemann W, et al. Comparison of (68)Ga-HBED-CC PSMA-PET/CT and multiparametric MRI for gross tumour volume detection in patients with primary prostate cancer based on slice by slice comparison with histopathology. Theranostics. 2017;7:228–37. https://doi.org/10.7150/thno.16638.CrossRefPubMedPubMedCentral

30.

Peeters STH, Heemsbergen WD, Koper PCM, van Putten WLJ, Slot A, Dielwart MFH, et al. Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol. 2006;24:1990–6. https://doi.org/10.1200/JCO.2005.05.2530.CrossRefPubMed

31.

Dearnaley DP, Sydes MR, Graham JD, Aird EG, Bottomley D, Cowan RA, et al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. Lancet Oncol. 2007;8:475–87. https://doi.org/10.1016/S1470-2045(07)70143-2.CrossRefPubMed

32.

Zamboglou C, Sachpazidis I, Koubar K, Drendel V, Wiehle R, Kirste S, et al. Evaluation of intensity modulated radiation therapy dose painting for localized prostate cancer using (68)Ga-HBED-CC PSMA-PET/CT: a planning study based on histopathology reference. Radiother Oncol. 2017;123:472–7. https://doi.org/10.1016/j.radonc.2017.04.021.CrossRefPubMed

33.

Koerber SA, Utzinger MT, Kratochwil C, Kesch C, Haefner M, Katayama S, et al. (68)Ga-PSMA11-PET/CT in newly diagnosed carcinoma of the prostate: correlation of intraprostatic PSMA uptake with several clinical parameters. J Nucl Med. 2017; https://doi.org/10.2967/jnumed.117.190314.

34.

Ristau BT, O’Keefe DS, Bacich DJ. The prostate-specific membrane antigen: lessons and current clinical implications from 20 years of research. Urol Oncol. 2014;32:272–9. https://doi.org/10.1016/j.urolonc.2013.09.003.CrossRefPubMed

35.

Thorwarth D, Notohamiprodjo M, Zips D, Müller A-C. Personalized precision radiotherapy by integration of multi-parametric functional and biological imaging in prostate cancer: a feasibility study. Z Med Phys. 2017;27:21–30. https://doi.org/10.1016/j.zemedi.2016.02.002.CrossRefPubMed

36.

Giesel FL, Sterzing F, Schlemmer HP, Holland-Letz T, Mier W, Rius M, et al. Intra-individual comparison of (68)Ga-PSMA-11-PET/CT and multi-parametric MR for imaging of primary prostate cancer. Eur J Nucl Med Mol Imaging. 2016;43:1400–6. https://doi.org/10.1007/s00259-016-3346-0.CrossRefPubMedPubMedCentral

37.

Gupta M, Choudhury PS, Hazarika D, Rawal S. A comparative study of (68)gallium-prostate specific membrane antigen positron emission tomography-computed tomography and magnetic resonance imaging for lymph node staging in high risk prostate Cancer patients: an initial experience. World J Nucl Med. 2017;16:186–91. https://doi.org/10.4103/1450-1147.207272.CrossRefPubMedPubMedCentral

38.

Vinsensia M, Choyke PL, Hadaschik B, Holland-Letz T, Moltz J, Kopka K, et al. (68)Ga-PSMA PET/CT and volumetric morphology of PET-positive lymph nodes stratified by tumor differentiation of prostate cancer. J Nucl Med. 2017; https://doi.org/10.2967/jnumed.116.185033.

39.

Öbek C, Doğanca T, Demirci E, Ocak M, Kural AR, Yıldırım A, et al. The accuracy of (68)Ga-PSMA PET/CT in primary lymph node staging in high-risk prostate cancer. Eur J Nucl Med Mol Imaging. 2017; https://doi.org/10.1007/s00259-017-3752-y.

40.

Schwenck J, Rempp H, Reischl G, Kruck S, Stenzl A, Nikolaou K, et al. Comparison of (68)Ga-labelled PSMA-11 and (11)C-choline in the detection of prostate cancer metastases by PET/CT. Eur J Nucl Med Mol Imaging. 2017;44:92–101. https://doi.org/10.1007/s00259-016-3490-6.CrossRefPubMed

41.

Bluemel C, Krebs M, Polat B, Linke F, Eiber M, Samnick S, et al. 68Ga-PSMA-PET/CT in patients with biochemical prostate Cancer recurrence and negative 18F-choline-PET/CT. Clin Nucl Med. 2016;41:515–21. https://doi.org/10.1097/RLU.0000000000001197.CrossRefPubMedPubMedCentral

42.

Jilg CA, Drendel V, Rischke HC, Beck T, Vach W, Schaal K, et al. Diagnostic accuracy of Ga-68-HBED-CC-PSMA-ligand-PET/CT before salvage lymph node dissection for recurrent prostate Cancer. Theranostics. 2017;7:1770–80. https://doi.org/10.7150/thno.18421.CrossRefPubMedPubMedCentral

43.

Pyka T, Okamoto S, Dahlbender M, Tauber R, Retz M, Heck M, et al. Comparison of bone scintigraphy and (68)Ga-PSMA PET for skeletal staging in prostate cancer. Eur J Nucl Med Mol Imaging. 2016;43:2114–21. https://doi.org/10.1007/s00259-016-3435-0.CrossRefPubMed

44.

Thomas L, Balmus C, Ahmadzadehfar H, Essler M, Strunk H, Bundschuh RA. Assessment of bone metastases in patients with prostate Cancer-a comparison between (99m)Tc-bone-scintigraphy and [(68)Ga]Ga-PSMA PET/CT. Pharmaceuticals (Basel). 2017;10 https://doi.org/10.3390/ph10030068.

45.

Stephenson AJ, Scardino PT, Kattan MW, Pisansky TM, Slawin KM, Klein EA, et al. Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol. 2007;25:2035–41. https://doi.org/10.1200/JCO.2006.08.9607.CrossRefPubMedPubMedCentral

46.

Tendulkar RD, Agrawal S, Gao T, Efstathiou JA, Pisansky TM, Michalski JM, et al. Contemporary update of a multi-institutional predictive nomogram for salvage radiotherapy after radical prostatectomy. J Clin Oncol. 2016; https://doi.org/10.1200/JCO.2016.67.9647.

47.

Interdisziplinäre Leitlinie der Qualität S3 zur Früherkennung, Diagnose und Therapie der verschiedenen Stadien des Prostatakarzinoms [Internet]. Available: https://www.leitlinienprogramm-onkologie.de/leitlinien/prostatakarzinom/. Accessed 9 May 2018.

48.

Afshar-Oromieh A, Holland-Letz T, Giesel FL, Kratochwil C, Mier W, Haufe S, et al. Diagnostic performance of (68)Ga-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: evaluation in 1007 patients. Eur J Nucl Med Mol Imaging. 2017;44:1258–68. https://doi.org/10.1007/s00259-017-3711-7.CrossRefPubMedPubMedCentral

49.

Eiber M, Maurer T, Souvatzoglou M, Beer AJ, Ruffani A, Haller B, et al. Evaluation of hybrid ⁶⁸Ga-PSMA ligand PET/CT in 248 patients with biochemical recurrence after radical prostatectomy. J Nucl Med. 2015;56:668–74. https://doi.org/10.2967/jnumed.115.154153.CrossRefPubMed

50.

Rauscher I, Düwel C, Haller B, Rischpler C, Heck MM, Gschwend JE, et al. Efficacy, predictive factors, and prediction nomograms for 68Ga-labeled prostate-specific membrane antigen-ligand positron-emission tomography/computed tomography in early biochemical recurrent prostate Cancer after radical prostatectomy. Eur Urol. 2018;73:656–61. https://doi.org/10.1016/j.eururo.2018.01.006.CrossRefPubMed

51.

Verburg FA, Pfister D, Heidenreich A, Vogg A, Drude NI, Vöö S, et al. Extent of disease in recurrent prostate cancer determined by [(68)Ga]PSMA-HBED-CC PET/CT in relation to PSA levels, PSA doubling time and Gleason score. Eur J Nucl Med Mol Imaging. 2016;43:397–403. https://doi.org/10.1007/s00259-015-3240-1.CrossRefPubMed

52.

Ceci F, Uprimny C, Nilica B, Geraldo L, Kendler D, Kroiss A, et al. (68)Ga-PSMA PET/CT for restaging recurrent prostate cancer: which factors are associated with PET/CT detection rate? Eur J Nucl Med Mol Imaging. 2015;42:1284–94. https://doi.org/10.1007/s00259-015-3078-6.CrossRefPubMed

53.

van Leeuwen PJ, Stricker P, Hruby G, Kneebone A, Ting F, Thompson B, et al. (68) Ga-PSMA has a high detection rate of prostate cancer recurrence outside the prostatic fossa in patients being considered for salvage radiation treatment. BJU Int. 2016;117:732–9. https://doi.org/10.1111/bju.13397.CrossRefPubMed

54.

Habl G, Sauter K, Schiller K, Dewes S, Maurer T, Eiber M, et al. (68) Ga-PSMA-PET for radiation treatment planning in prostate cancer recurrences after surgery: individualized medicine or new standard in salvage treatment. Prostate. 2017;77:920–7. https://doi.org/10.1002/pros.23347.CrossRefPubMed

55.

Shakespeare TP. Effect of prostate-specific membrane antigen positron emission tomography on the decision-making of radiation oncologists. Radiat Oncol. 2015;10:233. https://doi.org/10.1186/s13014-015-0548-8.CrossRefPubMedPubMedCentral

56.

Schiller K, Sauter K, Dewes S, Eiber M, Maurer T, Gschwend J, et al. Patterns of failure after radical prostatectomy in prostate cancer - implications for radiation therapy planning after (68)Ga-PSMA-PET imaging. Eur J Nucl Med Mol Imaging. 2017;44:1656–62. https://doi.org/10.1007/s00259-017-3746-9.CrossRefPubMed

57.

Lawton CAF, Michalski J, El-Naqa I, Buyyounouski MK, Lee WR, Menard C, et al. RTOG GU radiation oncology specialists reach consensus on pelvic lymph node volumes for high-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2009;74:383–7. https://doi.org/10.1016/j.ijrobp.2008.08.002.CrossRefPubMed

58.

Emmett L, Van Leeuwen P, Nandurkar R, Scheltema MJ, Cusick T, Hruby G, et al. Treatment outcomes from (68)GaPSMA PET CT informed salvage radiation treatment in men with rising PSA following radical prostatectomy: prognostic value of a negative PSMA PET. J Nucl Med. 2017; https://doi.org/10.2967/jnumed.117.196683.

59.

Zschaeck S, Wust P, Beck M, Wlodarczyk W, Kaul D, Rogasch J, et al. Intermediate-term outcome after PSMA-PET guided high-dose radiotherapy of recurrent high-risk prostate cancer patients. Radiat Oncol. 2017;12:140. https://doi.org/10.1186/s13014-017-0877-x.CrossRefPubMedPubMedCentral

60.

Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol. 1995;13:8–10. https://doi.org/10.1200/JCO.1995.13.1.8.CrossRefPubMed

61.

Habl G, Straube C, Schiller K, Duma MN, Oechsner M, Kessel KA, et al. Oligometastases from prostate cancer: local treatment with stereotactic body radiotherapy (SBRT). BMC Cancer. 2017;17:361. https://doi.org/10.1186/s12885-017-3341-2.CrossRefPubMedPubMedCentral

62.

Percutaneous High-dose Radiotherapy in Patients With Oligometastases of Prostate Carcinoma (Oli-P) [Internet]. Available: https://clinicaltrials.gov/ct2/show/NCT02264379. Accessed 9 May 2018.

63.

Wright GL, Mayer Grob B, Haley C, Grossman K, Newhall K, Petrylak D, et al. Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology. 1996;48:326–34. https://doi.org/10.1016/S0090-4295(96)00184-7.CrossRefPubMed

64.

Craft N, Chhor C, Tran C, Belldegrun A, DeKernion J, Witte ON, et al. Evidence for clonal outgrowth of androgen-independent prostate cancer cells from androgen-dependent tumors through a two-step process. Cancer Res. 1999;59:5030–6.PubMed

65.

Schlenkhoff CD, Knüpfer E, Essler M, Ahmadzadehfar H. Metastatic prostate Cancer with restored hormone-response after Radioligand therapy with 177Lu-PSMA-617. Clin Nucl Med. 2016;41:572–3. https://doi.org/10.1097/RLU.0000000000001200.CrossRefPubMed

66.

Hope TA, Truillet C, Ehman EC, Afshar-Oromieh A, Aggarwal R, Ryan CJ, et al. 68Ga-PSMA-11 PET imaging of response to androgen receptor inhibition: first human experience. J Nucl Med. 2017;58:81–4. https://doi.org/10.2967/jnumed.116.181800.CrossRefPubMedPubMedCentral

67.

Meller B, Bremmer F, Sahlmann CO, Hijazi S, Bouter C, Trojan L, et al. Alterations in androgen deprivation enhanced prostate-specific membrane antigen (PSMA) expression in prostate cancer cells as a target for diagnostics and therapy. EJNMMI Res. 2015;5:66. https://doi.org/10.1186/s13550-015-0145-8.CrossRefPubMedPubMedCentral

68.

Guler OC, Engels B, Onal C, Everaert H, Van den Begin R, Gevaert T, et al. The feasibility of prostate-specific membrane antigen positron emission tomography(PSMA PET/CT)-guided radiotherapy in oligometastatic prostate cancer patients. Clin Transl Oncol. 2017; https://doi.org/10.1007/s12094-017-1736-9.

69.

Henkenberens C, VON Klot CA, Ross TL, Bengel FM, Wester H-J, Katja H, et al. (68)Ga-PSMA ligand PET/CT-based radiotherapy for lymph node relapse of prostate Cancer after primary therapy delays initiation of systemic therapy. Anticancer Res. 2017;37:1273–9. https://doi.org/10.21873/anticanres.11444.CrossRefPubMed

70.

Bluemel C, Linke F, Herrmann K, Simunovic I, Eiber M, Kestler C, et al. Impact of (68)Ga-PSMA PET/CT on salvage radiotherapy planning in patients with prostate cancer and persisting PSA values or biochemical relapse after prostatectomy. EJNMMI Res. 2016;6:78. https://doi.org/10.1186/s13550-016-0233-4.CrossRefPubMedPubMedCentral

71.

Henkenberens C, von Klot CA, Ross TL, Bengel FM, Wester H-J, Merseburger AS, et al. (68)Ga-PSMA ligand PET/CT-based radiotherapy in locally recurrent and recurrent oligometastatic prostate cancer : early efficacy after primary therapy. Strahlenther Onkol. 2016;192:431–9. https://doi.org/10.1007/s00066-016-0982-z.CrossRefPubMed

Title: PSMA-PET based radiotherapy: a review of initial experiences, survey on current practice and future perspectives
Authors: Sebastian Zschaeck
Fabian Lohaus
Marcus Beck
Gregor Habl
Stephanie Kroeze
Constantinos Zamboglou
Stefan Alexander Koerber
Jürgen Debus
Tobias Hölscher
Peter Wust
Ute Ganswindt
Alexander D. J. Baur
Klaus Zöphel
Nikola Cihoric
Matthias Guckenberger
Stephanie E. Combs
Anca Ligia Grosu
Pirus Ghadjar
Claus Belka
Publication date: 01-12-2018
Publisher: BioMed Central
Published in: Radiation Oncology / Issue 1/2018
Electronic ISSN: 1748-717X
DOI: https://doi.org/10.1186/s13014-018-1047-5

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

PSMA-PET based radiotherapy: a review of initial experiences, survey on current practice and future perspectives

Abstract

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2018

A simple method for determining dosimetric leaf gap with cross-field dose width for rounded leaf-end multileaf collimator systems

Re-irradiation in lung disease by SBRT: a retrospective, single institutional study

Investigating rectal toxicity associated dosimetric features with deformable accumulated rectal surface dose maps for cervical cancer radiotherapy

Validation of new transmission detector transmission factors for online dosimetry: an experimental study

Effect of machine learning methods on predicting NSCLC overall survival time based on Radiomics analysis

Primary histiocytic sarcoma of the central nervous system: a case report with platelet derived growth factor receptor mutation and PD-L1/PD-L2 expression and literature review